APAC IPOs & Placements, Aequitas Research

Nicholas Tan

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

Aequitas: Cofoe Medical Technology A/H Listing - Recovering from Post-Pandemic Slump

Aequitas: Cofoe Medical A/H Listing - Discount to HK and International Med-Device Peers

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Cofoe Medical Technology / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cofoe-medical-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:45716:1" rel="noopener">Cofoe Medical Technology (1187 HK)</a> raised around US$136m in its Hong Kong IPO. </li>
<li>It was founded in 2009 (with its brand tracing back to 2007), and as per the prospectus, is a leading provider of home care medical devices in China.</li>
<li>We have covered various aspects of the deal in our previous note. In this note, we will talk about the demand and trading dynamics.</li>
</ul>



Cofoe Medical Technology (1187 HK) raised around US$136m in its Hong Kong IPO. 
It was founded in 2009 (with its brand tracing back to 2007), and as per the prospectus, is a leading provider of home care medical devices in China.
We have covered various aspects of the deal in our previous note. In this note, we will talk about the demand and trading dynamics.


Aequitas: Cofoe Medical IPO Trading - Weak Insti Subs but Cheaper than Peers